Loading quotes...

Forecast

The analysts' average price target is €151.30 (+8.15%). The median is €148.97 (+6.48%).

Buy
  13
Hold
  18
Sell
  0

Discussions in the community

There is no discussion about this asset yet.

Start discussion

  • PerkinElmer pays 2025 dividend of $0.28; payout $32.80 million

    PerkinElmer decided at the annual general meeting on a dividend for 2025 of $0.28 per share, unchanged from the previous year, totaling $32.80 million and representing a total payout down 4.79%. The dividend yield for 2025 is 0.29%; the share price in New York fell 10.01% over the year, and the total return including the dividend is -9.71%. FactSet also expects $0.28 for 2026 and estimates the dividend yield then at 0.33%. » More on finanzen.net

Historical dividends Dividends

All dividend metrics All metrics
In 2026, Revvity has already paid €0.24 in dividends. The last payout was in November.

Financials

In the last quarter, Revvity had revenue of €647.66m and net profit of €55.36m
(EUR) October 2026
YoY
Revenue 647.66m 8.48%
Gross profit 371.93m 48.40%
Net profit 55.36m 38.91%
EBITDA 84.54m 46.35%

Fundamentals

Metric Value
Market capitalization
€13.13bn
Number of shares
125.44m
52-week high/low
€154.42 - €102.80
Dividend yield
0.17%
Dividends TTM
€0.24
Beta
1.10
P/E ratio
68.31
PEG ratio
5.04
P/B ratio
2.37
P/S ratio
5.86

Company profile

PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for the environmental, food, and industrial markets that enable its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

Name
Revvity
CEO
Prahlad R. Singh
Headquarters Waltham, ma
USA
Website
Sector
Health Care
Industry
Health Care Equipment & Supplies
IPO
06/07/1965
Employees 16,700

Ticker symbols

Exchange Symbol
NYSE
PKI
Düsseldorf
PKN.DU
Frankfurt
PKN.F
London
0KHE.L
München
PKN.MU
SIX
PKN.SW
London Stock Exchange
0KHE.L
Tai
2636.TW
Ist
AYEN.IS
Pnk
ZHSHF
NYSE
RVTY
🍪

Parqet  uses cookies. Learn more